Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)
Although the development of selective CARM1 inhibitors presents significant challenges, it remains a highly promising endeavor due to its potential to greatly advance anticancer drug discovery. Various strategies, including PROTACs can be employed to inactivate the protein, leading to antitumor effects.
Authors
- Gianluca Sbardella (ORCID: https://orcid.org/0000-0003-0748-1145)
- Sabrina Castellano (ORCID: https://orcid.org/0000-0002-7449-3704)
- Alessandra Feoli (ORCID: https://orcid.org/0000-0002-8960-7858)
- Monica Viviano (ORCID: https://orcid.org/0000-0003-1118-790X)
- Ciro Milite (ORCID: https://orcid.org/0000-0003-1000-1376)
- Alessandra Cipriano (ORCID: https://orcid.org/0000-0002-9062-5914)
Institutions
- Medigene (Germany) (DE)
- University of Salerno (IT)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1080/13543776.2025.2600946
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00